Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jazz Pharmaceuticals is currently conducting a clinical study titled ‘An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.’ The study aims to evaluate the effectiveness and safety of Zanidatamab, in combination with Cisplatin and Gemcitabine, with or without a PD-1/L1 inhibitor, as a first-line treatment for HER2-positive biliary tract cancer. This study holds significant potential for improving treatment options for this aggressive cancer type.
The intervention being tested is Zanidatamab, an experimental drug administered intravenously. It is combined with standard chemotherapy drugs Cisplatin and Gemcitabine, and may include a PD-1/L1 inhibitor, either Durvalumab or Pembrolizumab, based on physician choice and local regulations.
The study is designed as a Phase 3, randomized, open-label trial with a parallel intervention model. Participants are randomly assigned to receive either the experimental treatment or standard care, with the primary goal of assessing treatment efficacy.
The study began on February 21, 2024, with primary completion expected by August 19, 2025. The last update was submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update from Jazz Pharmaceuticals could influence its stock performance positively, as successful results may enhance its market position in oncology. Investors should watch for developments, especially in comparison to competitors in the HER2-positive cancer treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.